RFB01016

About Rockfish Bio

Rockfish Bio is a preclinical-stage biotech focused on the burgeoning field of senolytics—therapies that clear senescent cells. The company's platform identifies compounds that exploit a metabolic vulnerability in senescent cells, offering a potentially safer and more targeted approach than first-generation senolytics. Its lead candidate, RFB01016, has shown promising preclinical results in extending healthspan and lifespan and reducing senescent cell burden across multiple tissues. The company is actively seeking funding to advance its pipeline and capitalize on the significant market opportunity in age-related diseases.

Therapeutic Areas